Overview
Retatrutide is Eli Lilly triple agonist — hitting GIP, GLP-1 and glucagon receptors simultaneously — and the most powerful weight-loss molecule ever tested in humans. Phase 2 results showed up to 24.2% average weight loss at 48 weeks, with the curve still descending when the trial ended.
It is not yet approved anywhere. Phase 3 trials are ongoing, and everything on the grey market is unregulated research material.
How It Works
Retatrutide combines the proven GIP/GLP-1 dual mechanism of tirzepatide with glucagon receptor activation. Glucagon raises energy expenditure — the body burns more calories at rest — and promotes fat oxidation in the liver.
Why three beats two
GLP-1 suppresses intake; glucagon increases output. The combination attacks energy balance from both sides, which likely explains the unprecedented trial results. Glucagon also raises blood sugar, but the GLP-1/GIP insulin effects more than compensate in practice.
Key Benefits
Weight loss — 24.2% average at 48 weeks in phase 2; some participants lost over 30%.
Liver fat — dramatic reductions in liver fat content, relevant for fatty liver disease.
Metabolic markers — improvements in glucose, lipids and blood pressure consistent with the class.
Energy expenditure — the glucagon component adds a mechanism no approved drug currently offers.
Side Effects & Considerations
Gastrointestinal side effects follow the class pattern. The glucagon component adds a modest increase in heart rate (peaking around 24 weeks, then declining) that researchers are watching closely. Skin sensitivity reactions have been reported.
The grey-market problem
Retatrutide is not approved, so every vial sold is unregulated research material of unknown purity and dose accuracy. The molecule is complex and expensive to synthesize correctly — the gap between label and contents is likely larger here than for simpler peptides. Phase 3 results and potential approval will define its real safety profile; until then, use is a gamble on both the molecule and the vendor.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Phase 2 trial design (reference) | 1-12 mg weekly after escalation | Once weekly subcutaneous | 48 weeks in trials | Not approved — no legitimate human dosing exists. Trial escalation started at 2 mg. |
Warnings
Investigational drug, not approved anywhere. Grey-market versions are unregulated and unverified. Heart rate increases observed in trials.